Authors' Reply to Coste et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet, D; Gandia, P; Montastruc, J L; Bousquet-Mélou, A; Lees, P; Ferran, A; Toutain, P L

doi:10.1007/s40262-019-00780-2

Authors' Reply to Coste et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet, D; Gandia, P; Montastruc, J L; Bousquet-Mélou, A; Lees, P; Ferran, A; Toutain, P L

Authors

D Concordet

P Gandia

J L Montastruc

A Bousquet-Mélou

P Lees

A Ferran

P L Toutain

Citation

Concordet, D., Gandia, P., Montastruc, J. L., Bousquet-Mélou, A., Lees, P., Ferran, A., & Toutain, P. L. (in press). Authors' Reply to Coste et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?". Clinical Pharmacokinetics, https://doi.org/10.1007/s40262-019-00780-2

Journal Article Type	Letter
Acceptance Date	Jun 1, 2019
Deposit Date	Jun 19, 2019
Publicly Available Date	Jun 20, 2019
Journal	Clinical Pharmacokinetics
Print ISSN	0312-5963
Electronic ISSN	1179-1926
Publisher	Adis
Peer Reviewed	Not Peer Reviewed
DOI	https://doi.org/10.1007/s40262-019-00780-2
Public URL	https://rvc-repository.worktribe.com/output/1382025